- American Lung Association.
American Lung AssociationDedicated to preventing lung disease and promoting lung health.
- Canadian immunization guide. (PDF: 4.4m) 7th ed.
National Advisory Committee on Immunization
Public Health Agency of Canada; 2006Presents information on the immunizing agents available in Canada and their use in the prevention of communicable diseases. Discusses recommendations on routine immunizations and answers queries from
providers regarding immunization.
- Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
Lexau Catherine A.,
Lynfield Ruth,
Danila Richard,
Pilishvili Tamara,
Facklam Richard,
Farley Monica M.,
Harrison Lee H.,
Schaffner William,
Reingold Arthur,
Bennett Nancy M.,
Hadler James,
Cieslak Paul R.,
Whitney Cynthia G. /
Active Bacterial Core Surveillance Team
- JAMA : Journal of the American Medical Association 2005;294(16):2043-51.
American Medical Association
» PubMed: 16249418Determines among adults aged 50 years or older whether incidence of invasive pneumococcal disease, disease characteristics, or the spectrum of patients acquiring these illnesses have changed over the 4 years since pneumococcal conjugate vaccine licensure.
- Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.
Whitney Cynthia G.,
Farley Monica M.,
Hadler James,
Harrison Lee H.,
Bennett Nancy M.,
Lynfield Ruth,
Reingold Arthur,
Cieslak Paul R.,
Pilishvili Tamara,
Jackson Delois,
Facklam Richard R.,
Jorgensen James H.,
Schuchat Anne. /
Active Bacterial Core Surveillance of the Emerging Infections Program Network
- New England Journal of Medicine 2003;348(18):1737-46.
Massachusetts Medical Society
» PubMed: 12724479Examined population-based data from the Active Bacterial Core Surveillance of the Centers for Disease Control and Prevention to evaluate changes in the burden of invasive disease.
- Getting your shots (CPS).
Canadian Paediatric Society; 2003Offers information on vaccines in Canada, written in plain language. Includes pamphlets on 5-in-1, measles, mumps and rubella, Diphtheria-tetanus-acellular pertussis, hepatitis B, chickenpox, pneumococcal vaccine, and meningococcal vaccine.
- Immunize your kids! (CCIAP). (PDF: 100k)
Canadian Coalition for Immunization Awareness & Promotion; 2009Describes how immunization works and lists recommended vaccinations for children. For best results print this brochure on letter-sized paper. (Choose File > Page Setup; under Orientation pick Landscape, and in the drop-down menu, under Paper pick Letter. Click OK and then print as usual.
- Invasive pneumococcal infections in Canadian children, 1998-2003: implications for new vaccination programs. (PDF: 156k)
Bettinger Julie A.,
Scheifele David W.,
Halperin Scott A.,
Kellner James D.,
Tyrrell Gregory. /
Canadian Paediatric Society’s Immunization Monitoring Program, Active
- Canadian Journal of Public Health 2007;98(2):111-5.
Canadian Public Health Association
» PubMed: 17441533Describes a sutudy which conducted active surveillance for invasive pneumococcal disease to assess the serotype and antibiotic resistance patterns in Canada prior to universal infant immunization programs.
- NACI Statement on recommended use of pneumococcal conjugate vaccine - Addendum. (PDF: 242k)
National Advisory Committee on Immunization
- Canada Communicable Disease Report 2003;29(ACS-8):14-15.
Public Health Agency of CanadaDetails the recommendations for resumption of immunization with the pneumococcal conjugate vaccine in the case of an infant or child’s pneumococcal immunization schedule being interrupted.
- NACI Statement on recommended use of pneumococcal conjugate vaccine.
National Advisory Committee on Immunization
- Canada Communicable Disease Report 2002;28(ACS-2):1-32.
» PubMed: 12728645
- Pneumococcal Disease: What it is, and do you need to worry about it? (PDF)
Canadian Coalition for Immunization Awareness & Promotion; 2009Provides basic information on pneumococcal infection (which can cause pneumococcal pneumonia, meningitis, bacteremia, or ear infection) and the two types of pneumococcal vaccine. The pneumococcal conjugate vaccine is part of the routine childhood immunization schedule; pneumococcal polysaccharide vaccine is recommended for adults 65 and older, and all individuals between 5 and 64 years of age who are at high risk of pneumococcal infection.
- Pneumococcal vaccination and risk of myocardial infarction. (PDF: 218k)
Lamontagne François,
Garant Marie-Pierre,
Carvalho Jean-Christophe,
Lanthier Luc,
Smieja Marek,
Pilon Danielle.
- Canadian Medical Association Journal 2008;179(8):773-7.A hospital-based case-control study that included patients considered to be at risk of myocardial infarction. Health databases were used to obtain hospital diagnoses and vaccination status. Patients who had been admitted for myocardial infarction were compared to those admitted to a surgical department in the same hospital for a reason other than myocardial infarction betwen 1997 and 2003.
- Population-based impact of pneumococcal conjugate vaccine in young children.
Peohling Katherine A.,
Lafleur Bonnie J.,
Szilagyi Peter G.,
Edwards Kathryn M.,
Mitchel Ed,
Barth Richard,
Schwartz Benjamin,
Griffin Marie R.
- Pediatrics 2004;114(3):755-61.
American Academy of Pediatrics
» PubMed: 15342850Determines the population impact of pneumococcal conjugate vaccine on pneumococcal-related diseases.
- Progress towards Canadian target coverage rates for influenza and pneumococcal immunizations.
- Canada Communicable Disease Report 2001;27(10):90-1.
Public Health Agency of CanadaEvaluates the progress towards national targets for influenza and pneumococcal immunization coverage rates.
- Publications : immunization (ON).
Ministry of Health and Long-Term CareProvides links to fact sheets on immunization.
- Unprotected people reports.
Immunization Action CoalitionIncludes case reports, personal testimonies, newspaper and journal articles about people who have suffered or died from vaccine-preventable diseases.
- Update on Pediatric Invasive Pneumococcal Disease and Recommended Use of Conjugate Pneumococcal Vaccines.
Public Health Agency of Canada; 2010This statement provides an update on the epidemiology of pneumococcal disease since the introduction of Prevnar® (Wyeth Pharmaceuticals), as well as information regarding a newly authorised conjugate vaccine against pneumococcal disease, Synflorix™ (GlaxoSmithKline Inc.). It is anticipated that both pediatric and adult pneumococcal immunization programs will be changing over the next few years, as other vaccines are in development. These new vaccines will be reviewed in one or more additional statements once they are authorised for use in Canada. The 23 valent polysaccharide vaccine will not be discussed in the current statement. Recommendations for its use remain unchanged.